1.
Thaci D, Papp K, Gordon K, Morita A, Gooderham M, Foley P, Alemano E, Kisa R, Elbez Y, Ren H, Banerjee S. An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study. J of Skin [Internet]. 2019Nov.9 [cited 2020Nov.27];30:S12. Available from: https://jofskin.org/index.php/skin/article/view/739